Effects of nitric oxide inhibitors in mice with bladder outlet obstruction by Pereira, Marcy Lancia et al.
ORIGINAL ARTICLE
356
Effects of nitric oxide inhibitors in mice with bladder outlet 
obstruction
_______________________________________________
Marcy Lancia Pereira 1, Carlos Arturo Levi D’ancona 2, Julio Alejandro Rojas-Moscoso 3, Antonio Celso 
Saragossa Ramos Filho 3, Fabiola Zakia Mónica 3, Edson Antunes 3 
1 Departamento de Cirurgia, Faculdade de Ciências Médicas - UNICAMP, Campinas, SP, Brasil; 
2 Departamento de Urologia, Faculdade de Ciências Médicas -  UNICAMP, Campinas, SP, Brasil; 3 Departamento 
de Farmacologia, Faculdade de Ciências Médicas -  UNICAMP, Campinas, SP, Brasil
ABSTRACT         ARTICLE INFO______________________________________________________________     ______________________
Purpose: To investigate the lower urinary tract changes in mice treated with L-NAME, 
a non-selective competitive inhibitor of nitric oxide synthase (NOS), or aminoguani-
dine, a competitive inhibitor of inducible nitric oxide synthase (iNOS), after 5 weeks 
of partial bladder outlet obstruction (BOO), in order to evaluate the role of constitutive 
and non-constitutive NOS in the pathogenesis of this experimental condition.
Materials and Methods: C57BL6 male mice were partially obstructed and randomly al-
located into 6 groups: Sham, Sham + L-NAME, Sham + aminoguanidine, BOO, BOO + 
L-NAME and BOO + aminoguanidine. After 5 weeks, bladder weight was obtained and 
cystometry and tissue bath contractile studies were performed.
Results: BOO animals showed increase of non-voiding contractions (NVC) and bladder 
capacity, and also less contractile response to Carbachol and Electric Field Stimulation. 
Inhibition of NOS isoforms improved bladder capacity and compliance in BOO animals. 
L-NAME caused more NVC, prevented bladder weight gain and leaded to augmented 
contractile responses at muscarinic and electric stimulation. Aminoguanidine dimin-
ished NVC, but did not avoid bladder weight gain in BOO animals and did not improve 
contractile responses.
Conclusion: It can be hypothesized that chronic inhibition of three NOS isoforms in 
BOO animals leaded to worsening of bladder function, while selective inhibition of 
iNOS did not improve responses, what suggests that, in BOO animals, alterations are 
related to constitutive NOS.
Keywords:
NG-Nitroarginine Methyl Ester; 
Nitric Oxide; Urinary Bladder; 
Ureteral Obstruction
Int Braz J Urol. 2017; 43: 356-75
_____________________
Submitted for publication:
August 15, 2015
_____________________
Accepted after revision:
August 07, 2016
_____________________
Published as Ahead of Print:
January 05, 2017
INTRODUCTION
Nitric oxide (NO) is synthesized from its 
precursor L-arginine via NO synthases (NOS), whi-
ch exist in three isoforms: neuronal (nNOS), endo-
thelial (eNOS) and inducible (iNOS). The first ones 
are constitutively expressed and produce small 
quantities of NO and the last one is induced by 
cytokines, infection or other stimuli and produces 
large amounts of NO. Mice obstructed for 5 weeks 
exhibit morphologic and functional disorders and 
these changes were attributed to enhanced expres-
sion of iNOS early after obstruction, which would 
be responsible for improving oxygenation during 
obstruction-induced ischemia (1). Although NO 
can be produced by several sources, including en-
dothelial cells, nerves, smooth muscle and urothe-
lium, studies demonstrated that major sites of NO 
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release were urothelium and afferent nerves (2).
Treatment of BOO rats with aminoguani-
dine, a competitive inhibitor of iNOS, has shown 
good results, as decreases in iNOS ameliorated 
functional and fibrotic changes in the bladder (3, 
4). The same consequences have been observed 
in iNOS knockout mice (1, 4). Treatment with L-
-NAME, a non-selective competitive inhibitor of 
NOS, inhibited generation of nitrotyrosine, which 
is produced by nitrogen reactive species and, as 
consequence, improved bladder contraction (5). 
However, another study showed that a feeding 
diet rich in L-arginine was beneficial for rabbits 
with 2 weeks of severe BOO (6).
In the current study, we investigated lower 
urinary tract changes in mice treated with L-NA-
ME or aminoguanidine after 5 weeks of BOO, since 
these drugs represent non-selective and selective 
NOS inhibitors, respectively.
MATERIALS AND METHODS
Animals and Experimental Groups
The experimental protocols were appro-
ved by the Ethical Principles in Animal Research 
adopted by the Brazilian College for Animal Ex-
perimentation (COBEA, No 2030-1). Male C57BL6 
mice (25-30g), 8-9 weeks old, were used and ran-
domly allocated into six experimental groups: 
Sham (Sham-operated), Sham + L-NAME (Sham 
that received L-NAME), Sham + aminoguanidine 
(Sham that received aminoguanidine), BOO (blad-
der outlet obstruction), BOO + L-NAME (BOO that 
received L-NAME) and BOO + aminoguanidine 
(BOO that received aminoguanidine). Doses of L-
-NAME (150mg/Kg) and aminoguanidine (20mg/
Kg) were chosen according to previous study (7). 
All animals were placed into individual cages with 
food ad libitum and received drugs given in the 
drinking water immediately after surgery for a 
period of 5 weeks, when all in vitro and in vivo 
studies were performed.
Surgical Procedures
Animals were anesthetized by intraperito-
neal injection of ketamine (2mg/Kg) and xylazine 
(30mg/Kg) and placed in the supine position. A 
lower midline abdominal incision was made and, 
after exposure of the bladder and proximal ure-
thra, partial BOO was created by tying a 6-0 nylon 
suture around the urethra. A 0.6mm diameter tu-
bing was used as a guide to prevent total urethral 
occlusion. In Sham group, identification of bladder 
and proximal urethra was done, with no further 
surgical manipulation. Both abdomen muscles and 
skin were closed with a 6-0 nylon suture.
In vivo and in vitro bladder functional as-
sessment
Bladder weights
Bladders were carefully withdrawn and 
weighted. Also, mice were weighted for normali-
zation of values and the ratio bladder weight (mg) 
to body weight (g) was obtained. This parameter 
was used to verify if BOO animals exhibited bla-
dder weight increase, showing that pathological 
alterations due to this condition, imposed by sur-
gery, has occurred.
Filling Cystometry
Animals were anesthetized by intraperito-
neal injection of urethane (1.2g/Kg) and a lower 
midline incision was made to expose the bladder. 
A 25-gauge butterfly cannula was inserted into 
the bladder dome and was connected via a 3-way 
stopcock to a pressure transducer (AD Instruments, 
Sydney-NSW, Australia) and infusion pump (Har-
vard Apparatus, Holliston, MA). After bladder 
emptying, saline solution at room temperature 
was infused at a rate of 0.6mL/h until detrusor 
equilibration and then, counted for 30 minutes af-
ter the end of the first micturition cycle. Pressure 
registers were obtained by a Powerlab 4/30 data 
acquisition (6.0 system, AD Instruments, Sydney-
-NSW, Australia). Maximum detrusor pressure was 
defined as the peak of intravesical pressure during 
a micturition. Bladder capacity was determined as 
the total infused volume immediately before the 
first micturition. Compliance was measured as 
bladder capacity divided by the maximum detru-
sor pressure minus baseline pressure. Non-voiding 
contractions (NVC) were defined as increases in 
intravesical pressure (>4mmHg) not associated 
with release of urine through urethra. Micturition 
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frequency was measured considering the number 
of micturition cycles within 30 minutes. Threshold 
pressure was defined as the pressure immediately 
before micturition (8). Bladders of mice used for 
cystometry were not used in the other experiments.
Tissue bath
Animals were killed by inhalation of CO2. 
Bladders were rapidly dissected, removed, wei-
ghted and put immediately in a physiologic saline 
solution of Krebs-Henseleit (NaCl 117mM, NaHCO3 
25mM, C6H1206 11mM, KCl 4.7mM, NaHPO4 1.2mM, 
MgSO47H2O 1.2mM and CaCl22H2O 2.5mM, pH 
7.4). Two longitudinal muscle strips with intact 
urothelium were obtained from the bladder body, 
measuring 2 x 2 x 10mm and were mounted in 
10mL organ baths containing Krebs-Henseleit so-
lution at 37ºC bubbled with a gas mixture of 95% 
O2 and 5% CO2. Changes in isometric force were 
recorded using a computer Software (PowerLab 
v.7.0 system, AD Instruments, Sydney-NSW, Aus-
tralia). The resting tension was adjusted to 5mN 
at the beginning of the experiments, the equili-
bration period was 60 minutes and the bathing 
medium was changed every 15 minutes.
Cumulative concentration-response cur-
ves to the full muscarinic agonist Carbachol (1ƞM 
to 30μM) were constructed using one-half log 
unit. Nonlinear regression analysis to determine 
the pEC50 was carried out using Graph Pad Prism 
(Graph Pad Software, Inc., San Diego, CA, USA) 
with the constraint that F=0. All concentration–
response data were evaluated for a fit to a logistics 
function in the form: E = Emax / ([1 + (10c/10x)n] + 
F), where E is the maximum response produced by 
agonists; c is the logarithm of the EC50, the con-
centration of drug that produces a half-maximal 
response; x is the logarithm of the concentration 
of the drug; the exponential term, n, is a curve-
-fitting parameter that defines the slope of the 
concentration–response line, and F is the response 
observed in the absence of added drug. Data were 
normalized to the wet weight of the respective uri-
nary bladder strips, and the values of Emax were 
represented in mN/mg.
Bladder strips were stimulated with Elec-
tric Field Stimulation (EFS at 2, 4, 8 and 16Hz), 
50V, during 0.2ms and an interval of 2 minutes 
between pulses. Responses were recorded and ma-
ximal tensions compared, expressed by mN/mg.
Statistical analysis
The values recorded were mean±SEM, 
and the statistical significances were determined 
by One-Way ANOVA followed by the Tukey test. 
P<0.05 was considered significant. InStat© was 
used for statistical analysis.
Drugs
No-Nitro-L-arginine methyl ester hydro-
chloride (L-NAME), urethane, Carbachol and ami-
noguanidine hemisulfate were obtained from Sig-
ma Chem. Co. (St Louis, MO).
RESULTS
Bladder weights
Bladder outlet obstruction (BOO) animals 
showed increased bladder weight to body weight 
ratio (P<0.001), almost 2-fold when compared to 
Sham animals. Oral treatment with L-NAME in BOO 
animals decreased bladder weight to body weight 
(P<0.001). Treatment with aminoguanidine had no 
significant effect on this parameter (Figure-1).
Filling Cystometry
A total of 9 Sham, 6 Sham + L-NAME, 6 
Sham + aminoguanidine, 13 BOO, 6 BOO + L-NA-
ME and 7 BOO + aminoguanidine were evaluated. 
Figure-2 represents cystometric profiles obtained 
after 5 weeks of surgical procedures for all experi-
mental groups.
BOO animals showed more NVC and higher 
compliance than Sham. Treatment with L-NAME 
increased non-voiding contractions and dimi-
nished bladder capacity and compliance in BOO 
animals. BOO mice treated with aminoguanidine 
showed less NVC and lower bladder capacity. Al-
though a tendency of increase in micturition fre-
quency caused by L-NAME and aminoguanidine in 
BOO mice was observed, there were no statistical 
differences for this parameter, for maximum detru-
sor pressure or threshold pressure. Sham mice tre-
ated with aminoguanidine showed lower bladder 
capacity (Figure-3 and Table-1).
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Figure 1 - Bladder weight to body weight ratio in Sham and BOO mice treated or not with L-NAME or aminoguanidine 
for 5 weeks.
Figure 2 - Representative Cystometrograms in Sham (A), Sham + L-NAME (B), Sham+aminoguanidine (C), BOO - Bladder 
outlet obstruction (D), BOO + L-NAME (E) and BOO + aminoguanidine (F) groups. Arrows indicate micturition peaks.
***P<0.001 versus Sham. # # # P<0.001 versus BOO.
A
C
E
B
D
F
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* P<0.05 versus Sham; ** P<0.01 versus Sham; # P<0.05 versus BOO;
## P<0.01 versus BOO; ++ P<0.01 versus Sham + l-NAMe.
Figure 3 - Cystometric parameters in Sham and BOO mice treated or not with L-NAME or aminoguanidine for 5 weeks: non-
voiding contractions (A), threshold pressure (B), maximum detrusor pressure (C), compliance (D), bladder capacity (E) and 
micturition frequency (F).
A
C
E
B
D
F
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Tissue bath
Cumulative addition of the muscarinic 
agonist Carbachol (1ƞM to 30μM) to bladder pre-
parations produced concentration-dependent con-
tractions (Figure-4 and Table-2). Sham + L-NAME 
mice showed higher responses compared to Sham. 
BOO and BOO + aminoguanidine groups exhibi-
ted a significant decrease in maximal responses 
to this agonist. The pEC50 values for Carbachol did 
not change significantly for any group.
Table 1 - Cystometric parameters evaluated for each experimental group. NvC: non-voiding contractions.
Experimental Group NVC (n/min) Micturition frequency 
(n/min)
Threshold pressure 
(mmHg)
Maximum detrusor 
pressure (mmHg)
Bladder capacity 
(mL)
Compliance
(mL/mmHg)
Sham (n=9) 0.079 ± 0.034 0.173 ± 0.041 5.406 ± 0.985 15.288 ± 1.859 0.252 ± 0.034 0.059 ± 0.011
Sham + L-NAME (n=6) 0.174 ± 0.039 0.201 ± 0.046 9.168 ± 1.753 11.673 ± 1.306 0.147 ± 0.029 0.017 ± 0.001 **
Sham + aminoguanidine (n=6) 0.117 ± 0.045 0.145 ± 0.029 5.045 ± 1.146 15.933 ± 1.542 0.115 ± 0.026 0.026 ± 0.006 *
BOO (n=13) 0.215 ± 0.059 * 0.183 ± 0.036 8.496 ± 1.294 12.965 ± 2.741 0.382 ± 0.052 * ++ 0.056 ± 0.015
BOO + L-NAME (n=6) 0.388 ± 0.125 * 0.314 ± 0.078 13.155 ± 2.329 13.808 ± 2.905 0.108 ± 0.021 # # 0.001 ± 0.001 # #
BOO + aminoguanidine (n=7) 0.050 ± 0.021 # 0.297 ± 0.074 8.717 ± 1.785 10.133 ± 1.114 0.151 ± 0.046 # # 0.026 ± 0.011 # #
* P<0.05 versus Sham; # P<0.05 versus BOO; # # P<0.01 versus BOO; ++ P<0.01 versus Sham + l-NAMe.
EFS induced a frequency-dependent incre-
ase in the amplitude of contractions in isolated 
bladder smooth muscle. BOO animals showed lo-
wer contraction when compared to Sham animals 
at all frequencies evaluated. L-NAME BOO treated 
animals showed decreased contraction at 2 and 
4Hz compared to Sham + L-NAME and increased 
contraction compared to BOO mice at 8 and 16Hz. 
There was no difference for aminoguanidine trea-
ted animals (Figure-5 and Table-3).
Figure 4 - Bladder smooth muscle contractions to Carbachol in Sham and BOO mice treated or not with L-NAME or 
aminoguanidine for 5 weeks.
*** P<0.001 versus Sham. # # # P<0.001 versus BOO.
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Table 2 - Maximal responses (Emax) and Potency (pEC50) to Carbachol (Cch) in bladder smooth muscle. Data were obtained 
in Sham and BOO animals, treated or not with L-NAME or aminoguanidine.
Experimental group Emax (mN/mg) pEC50
Sham (n=9) 1.29 ± 0.13 6.43 ± 0.21
Sham + L-NAME (n=3) 3.06 ± 0.40*** 6.38 ± 0.17
Sham + aminoguanidine (n=4) 1.40 ± 0.27 6.15 ± 0.16
BOO (n=10) 0.49 ± 0.09* 6.30 ± 0.17
BOO + L-NAME (n=6) 1.08 ± 0.12 +++# 6.04 ± 0.10
BOO + aminoguanidine (n=3) 0.55 ± 0.11* 6.35 ± 0.17
* P<0.05 versus Sham; *** P<0.001 versus Sham; # P<0.05 versus BOO. +++ P<0.001 versus Sham + l-NAMe.
Figure 5 - Contractile responses to electrical-field stimulation (EFS; 2-16 Hz) in bladders from Sham and BOO mice, treated 
or not with L-NAME or aminoguanidine for 5 weeks.
* P<0.05 versus Sham; ** P<0.01 versus Sham; *** P<0.001 versus Sham; # P<0.05 versus BOO; # # P<0.01 versus BOO; # # # P<0.001 versus BOO; + P< 0.05 versus 
Sham + l-NAMe.
DISCUSSION
Despite the high prevalence of benign 
prostatic hyperplasia among men, the mechanis-
ms responsible for voiding dysfunction induced 
by bladder outlet obstruction (BOO) are not well 
understood. Research and development of appro-
priate therapies include the use of animal models 
in order to understand the physiological control of 
urinary continence, as well as pathophysiological 
conditions involved in bladder dysfunction (9).
Several studies used rats (3, 4), mice (1, 10, 
11), rabbits (12), guinea pigs (13) and pigs (14) to 
mimic BOO, whose structural and physiological 
changes of the bladder wall are similar to those 
observed in men suffering from BPH (9).
We used an established animal model of 
BOO. We found that BOO mice showed increased 
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Table 3 - Contraction (mN) produced by electric stimulation in isolated bladder smooth muscle. 
Experimental Group 2 Hz 4 Hz 8 Hz 16 Hz
Sham (n=9) 0.639 ± 0.190 0.977 ± 0.288 1.645 ± 0.372 2.129 ± 0.388
Sham + L-NAME (n=5) 0.686 ± 0.249 1.018 ± 0.352 1.539 ± 0.445 1.836 ± 0.459
Sham + aminoguanidine (n=4) 0.316 ± 0.077 0.520 ± 0.138 0.976 ± 0.252 1.532 ± 0.382
BOO (n=10) 0.108 ± 0.031 * 0.191 ± 0.052 * 0.285 ± 0.077 ** 0.398 ± 0.106 ***
BOO + L-NAME (n=8) 0.220 ± 0.038 + 0.369 ± 0.066 + 0.754 ± 0.139 # 0.939 ± 0.153 # #
BOO + aminoguanidine (n=3) 0.236 ± 0.076 0.322 ± 0.095 0.469 ± 0.143 0.610 ± 0.203
* P<0.05 versus Sham; ** P<0.01 versus Sham; *** P<0.001 versus Sham; # P<0.05 versus BOO; # # P<0.01 versus BOO; + P<0.05 versus Sham + l-NAMe.
bladder weight to body weight ratio, almost 2-fold 
when compared to Sham animals (2.45±0.17 and 
1.25±0.05, respectively), according to 2.5-fold ob-
served in a study with female mice (10). In fact, 
mice 1 week after obstruction already have a rapid 
increase in bladder mass, which worsened 3 and 5 
weeks after the surgical procedure (11). Similarly, 
rats and rabbits have increased blood flow after 24 
hours of obstruction, which could be the first sti-
mulus for hypertrophy (12, 15). This event occurs 
due to stretch of the bladder wall components, lea-
ding to thickening of epithelium, muscle layer and 
serosa (16) and increase in synthesis and deposi-
tion of collagen (17). After initial bladder function 
compensation, blood flow tends to diminish (18) 
and, as the process becomes chronic, more hypo-
xic-reperfusion areas can be observed in muscular 
layer (19). The increased wall thickness and wall 
tension result in cyclical ischemia-reperfusion du-
ring and subsequent to each voiding contraction 
(19, 20) and cause progressive deterioration of bla-
dder function (17). The oxidative stress increases 
the production of reactive oxygen species (ROS), 
leading to enhanced malondialdehyde (MDA) and 
diminished superoxide dismutase (SOD). Free radi-
cals originating from ischemia-reperfusion injury 
are one of primary etiologies in obstructed bladder 
dysfunction (21). A 4-week BOO female mice study 
revealed increased edema and lymphocytic infil-
trate in the lamina propria, and hypoxia was seen 
in the urothelium, lamina propria and detrusor (5). 
Six-week BOO male investigation showed increase 
in muscular hypertrophy and fibrosis (22).
Treatment with the non-selective NOS 
inhibitor L-NAME showed decrease in blad-
der weight. In rats treated for 4 weeks with the 
same drug, morphometric studies showed incre-
ased thickness of trigone smooth muscle without 
affecting detrusor smooth muscle (DSM) thick-
ness (23). Moreover, although early administra-
tion of L-NAME enhances ischemic damage at 
the beginning of the obstructive process, it inhi-
bits the generation of nitrotyrosine and results 
in preservation of nerve density, reducing initial 
free radical damage associated with BOO (5). On 
the other hand, at chronic obstruction, L-NAME 
also prevents increases in blood flow and ROS 
generation from the compromised mitochondria, 
but nitrotyrosine production enhances and leads 
to worsen in bladder function (24).
In contrast, aminoguanidine treatment did 
not induce significant reduction of bladder weight 
in BOO mice, which is in contrast to another study 
(3), when 2 weeks BOO iNOS knock out and ami-
noguanidine treated rats presented less fibrosis. 
In both 3 and 6 week obstructed rats, eNOS acti-
vity decreases when compared to Sham animals, 
but nevertheless is higher than iNOS activity (21). 
Hypertrophied rat obstructed bladders exhibited 
weak nNOS expression after 3 and 6 weeks (3). 
In our study, this indicate that inhibition of iNOS 
alone did not affected bladder gain mass, unlike 
inhibition of the three isoforms of NOS had signi-
ficant results.
Urodynamic characteristics normally cor-
relate with bladder weight, but detrusor overac-
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tivity in BOO animals may develop without an 
increase in bladder weight, suggesting that major 
disturbances caused by BOO may lie in the affe-
rent signaling pathway (25). Some authors pro-
pose that NO may be involved in the regulation 
of the threshold for bladder afferent firing (26). 
Moreover, the effects of urothelial NO may not 
be mediated by a direct action on smooth mus-
cle, because DSM lack soluble guanylate cyclase 
(GC), an important component in NO-mediated 
relaxation (27, 28).
Although maximum detrusor pressure and 
capacity did not reveal significant differences be-
tween BOO and Sham animals, the first parame-
ter tended to increase, following compliance, that 
was higher in BOO mice. This is in agreement with 
studies with BOO rats (4, 29-31), but is different 
from what has previously been demonstrated in 
the obstructed mouse bladder (9, 11). Moreover, 
BOO mice had more NVC than Sham, similarly 
to another studies with mice and rats (4, 11, 31). 
In the unstable bladder, alterations of the smoo-
th muscle can be a consequence of the “patchy 
denervation” of the detrusor (32), mediated by 
oxidative stress, since reduced amount of gluta-
thione, the most abundant non-protein thiol with 
antioxidant capacity, was observed in BOO blad-
ders (33). Predominance of protrusions junctions 
and ultra-close cell abutments in BOO (34) lead 
to more sensibility and lose of synchronism, what 
features detrusor overactivity (3).
L-NAME BOO treated animals had more 
NVCs than BOO, suggesting worsening of bladder 
function. The same result was found in chronically 
L-NAME treated rats (35) and was due to DSM 
super sensitivity to muscarinic agonists via incre-
ases in the levels of [3H] inositol phosphate (IP3), 
accompanied by reduction of β3-adrenoceptor-
mediated DSM relaxations (23). Aminoguanidine 
treatment decreased NVC in BOO mice, as shown 
in BOO rats treated with the same drug, due to at-
tenuation in fibrosis. Studies using iNOS knockout 
mice instead of aminoguanidine treatment present 
concordance of results, in which NO contributes to 
ischemic injury and inhibition of iNOS is of thera-
peutic benefit (4).
Although with no significant difference in 
micturition frequency for L-NAME and amino-
guanidine BOO treated groups, tendency of incre-
ase in this parameter was according to the smaller 
bladder capacity observed for these animals.
In vitro muscle physiology studies showed 
that BOO strips were able to generate less tension 
in response to cholinergic stimulation and EFS. 
Other authors have already demonstrated that 
bladder function maintains stable until 3 weeks 
post obstruction, but after 5 weeks there is im-
pairment in detrusor function (1, 11). Unstable 
human bladders frequently show patchy denerva-
tion of the muscle bundles. Some muscle fascicles 
may be completely denervated, while neighboring 
bundles appear normal. Other regions may show 
intermediate innervation. The areas of reduced 
innervation become infiltrated with connective 
tissue (36). Guinea-pig obstructed bladders also 
present denervation, diminished response to EFS 
and muscarinic agonists (33).
Aminoguanidine treated animals had no 
role in bladder contraction evaluated by tissue 
bath experiments. However, L-NAME leaded to 
higher contraction in BOO mice. Obstructed rab-
bits treated with L-NAME presented higher bla-
dder contraction to Carbachol and EFS 3 and 7 
days post obstruction, in addition to less genera-
tion of nitrotyrosine and, consequently, reduction 
in membrane damage. This could account for the 
augmentation of contractile function and higher 
nerve densities observed for these animals (5). 
Another research with BOO rabbits treated with 
L-NAME showed reduced apoptosis due to ische-
mia-reperfusion and had significantly increase in 
contractile responses compared with non-treated 
animals (37). In rats chronically treated with L-
-NAME, it was observed that DSM relaxations me-
diated by β3-adrenoceptors reduced, what suggests 
that prolonged NO deficiency leads to an overac-
tive bladder (23).
CONCLUSIONS
L-NAME resulted in less bladder mass 
gain. The higher contractile responses and the in-
crement in NVC suggests that the overactivity al-
ready presented by the BOO animals became worse. 
Although aminoguanidine treatment had decreased 
NVC, it leaded to reduced bladder capacity, did not 
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prevent the increase in bladder weight and was 
not effective in ameliorating contractile responses. 
Taking the results together, it can be hypothesized 
that chronic inhibition of three NOS isoforms in 
BOO animals leaded to worsening of bladder func-
tion, while selective inhibition of iNOS did not im-
prove responses, what suggests that, in BOO ani-
mals, alterations are related to constitutive NOS.
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